Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

This phase II trial studies the effects of stereotactic body radiation therapy (SBRT) and the timing of treatment with androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) in treating patients with hormone sensitive prostate cancer that has spread from where it first started to other places in the body (metastatic), and that has come back after a period of improvement (recurrent). It also studies the effects of salvage radiation therapy (sXRT) on prostate cancer and to see if radiation to the pelvis helps prevent prostate cancer from spreading elsewhere. SBRT is a

Trial Details

NCT ID

NCT06378866

Phase

PHASE2

Sponsor

Mayo Clinic

Status

RECRUITING

Cancer Type

Hormone-Sensitive Prostate Cancer

Interventions

Abiraterone
Apalutamide
Biospecimen Collection
Bone Scan
Computed Tomography
Darolutamide

Locations (sample)

Phoenix, Arizona, United States|33.44838,-112.07404
Jacksonville, Florida, United States|30.33218,-81.65565
Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

Age ≥ 18 years
Disease characteristics:
DEVIATE (Groups A and B only):
Clinical confirmation of metachronous (metastatic) recurrent hormone-sensitive prostate cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hormone-Sensitive Prostate Cancer Trials on Trialify →